The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Read more about The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease.
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Read more about Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Read more about Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Read more about Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. Read more about Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Read more about A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Read more about Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Ionizing radiation: an element of danger in every procedure. Read more about Ionizing radiation: an element of danger in every procedure.
Osteosarcoma in children 5 years of age or younger at initial diagnosis. Read more about Osteosarcoma in children 5 years of age or younger at initial diagnosis.
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Read more about Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
